

CSIR-CDRI to develop safer drug for heart attack and stroke

11 June 2021 | News

Ties up with UP-based Marc Laboratories for drug development



CSIR – Central Drug Research Institute (CDRI), Lucknow is committed to support Pharma Cluster in Uttar Pradesh and has tied up with UP-based Marc Laboratories, a young progressive enterprise with operating base in 13 other states.

It has signed an agreement for the development of a synthetic compound S-007-867 as modulator of blood coagulation cascade, in particular as inhibitor of collagen induced platelet aggregation. This may be helpful in treating patient population of coronary and cerebral artery diseases.

The institute has recently obtained the permission to initiate the Phase I clinical trials for the drug.

The compound S-007-867 significantly inhibits collagen mediated platelet activation and subsequently reduces the release of ATP from dense granules and thromboxane A₂ via COX1 activation. Thus, it effectively maintains blood flow velocity and delays vascular occlusion (blockage of the blood vessel, usually with a clot) and inhibits thrombogenesis (formation of blood clot) without compromising hemostasis.

This drug has less bleeding risk as compared to presently existing therapies for coronary and cerebral artery diseases. In animal experiments, the compound elicited better antithrombotic protection than the standard of care with minimal bleeding tendency.

Prophylactic use of this compound could be useful for COVID -19 induced complications.